Brief: Japan Approves Nuvation Bio’s IBTROZITM for Advanced ROS1-Positive Non-Small Cell Lung Cancer
19/09/2025 12:39
Sept 19 (Reuters) - Nuvation Bio Inc NUVB.N: NUVATION BIO RECEIVES APPROVAL FROM JAPAN’S MINISTRY OF HEALTH, LABOUR AND WELFARE FOR IBTROZITM FOR PATIENTS WITH ADVANCED ROS1-POSITIVE NON-SMALL CELL LUNG CANCER NUVATION BIO INC: IBTROZI WILL BE MARKETED IN JAPAN BY NIPPON KAYAKU NUVATION BIO: UPON FIRST ESTABLISHMENT OF REIMBURSEMENT PRICE IN JAPAN, CO TO RECEIVE A USD $25 MILLION MILESTONE PAYMENT Source text: ID:nBwblnL9ga Further company coverage: NUVB.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvation Bio
See all newsBrief: Nuvation Bio To Expand Pivotal Phase 3 Sigma Study Of Safusidenib For Idh1-Mutant Glioma To Six European Countries
Brief: Nuvation Bio To Report Third Quarter 2026 Financial Results And Provide Business Update On November 4, 2026
U.S. RESEARCH ROUNDUP-Everpure, Marvell Technology, Okta
Nuvation Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Nuvation Bio Q2 revenue beats estimates on IBTROZI growth